SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
SocialPicks Community
JNJ undervalued
JNJ
|
|
|
+1.68%
in
110 days
JNJ is a market leading company that Warren Buffett acknowledges has a competitive advantage. I have analysed the fundamentals myself on a basic level and found the company to provide satisfactory returns at the current price. Analysts are also saying that JNJ is undervalued.
|
BioMedReports: FDA Calendar Updates
JNJ
|
|
|
+3.85%
in
119 days
<> Below is a summary of updates to the BioMedReports.com FDA Calendar , which includes a database of 260 entries as of 7/15/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of BioMedReports.com , the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pending late-stage clini...
|
FDA Calendar Updates: ABII, BMRN, JNJ, OSIP, Roche
JNJ
|
|
|
+2.22%
in
2 days
(closed on 07/15/09)
<> Below is a summary of updates to the <font> BioMedReports.com FDA Calendar </font> , which includes a database of 254 entries as of 7/13/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of <font> BioMedReports.com </font> , the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pendin...
|
FDA, Clinical Trial Updates: Heart Stents, Cholesterol in the News
JNJ
|
|
|
+3.24%
in
54 days
(closed on 07/13/09)
<> Below is a summary of updates to the <font> BioMedReports.com </font> database of over 200 entries included in the <font> FDA and Clinical Trial Calendars </font> . The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision deadline dates while the Clinical Trial Calendar encompasses pending clinical trial results (with a focus on late-stage, Phase 3 trials), pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), and pending re-submissions to the FDA fo...
|
FDA Calendar Updates: ACUS, APPY, APPA, ALKS, JNJ
JNJ
|
|
|
-0.32%
in
2 days
(closed on 05/20/09)
<> Below is a summary of updates to the <font> BioMedReports.com </font> database of over 200 entries included in the <font> FDA and Clinical Trial Calendars </font> . The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision deadline dates while the Clinical Trial Calendar encompasses pending clinical trial results (with a focus on late-stage, Phase 3 trials), pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), and pending re-submissions to the FDA fo...
|
From the Blogosphere
Wright Receives FDA Approval – Analyst Blog
|
|
|
Wright Medical Group, Inc. (WMGI) recently received the Food and Drug administration (FDA) approval to market its CONSERVE Plus Total Hip Resurfacing System in the U.S. The new system, which has received FDA approval, provides surgeons with a bone-conserving alternative to traditional total hip replacement.
With the FDA approval, Wright Medical can now market CONSERVE Plus in the original femoral and acetabular component configuration in the U.S. as specified in its PreMarket Approval (PMA) application with the FDA. The company also intends to develop additional enhancements to the system...
|
Zacks Analyst Blog Highlights: Boston Scientific Corporation, Johnson & Johnson, Medtronic Inc., Abbott Laboratories and St. Jude Medical Inc. – Press Releases
|
|
|
For Immediate Release Chicago, IL – November 11, 2009 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Boston Scientific Corporation (BSX), Johnson & Johnson (JNJ), Medtronic Inc. (MDT), Abbott Laboratories (ABT) and St. Jude Medical Inc. (STJ). Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513 <><>Here are highlights from Tu...
|
BSX Settles, Lowers Results – Analyst Blog
|
|
|
Boston Scientific Corporation (BSX) settled its $296 million lawsuit with the U.S. Department of Justice (DOJ) related to product advisories issued by its Guidant subsidiary in 2005. The litigation pertained to alleged violations of the Food, Drug, and Cosmetic Act by Guidant. The allegations were reported prior to Boston’s acquisition of Guidant in 2006.
Boston has recorded the litigation expense in its third quarter of fiscal 2009 results and updated its income statement accordingly. The expense has lowered the company’s GAAP earnings per share by 19 cents into a loss per share of 6 cent< />< />< />< />< />< /><><><><><><><><>< /><>< /><>< /><>< /><>< /><>< /><>< /><><>< /><>< /><>< />< />...
|
Notable ETF Movers: PGM, XLV, SMH Up; UNG, KRE, FXI, AGQ, XME Down
|
StreetInsider.com Notable ETF Movers:HIGHER:<> iPath DJ AIG Platinum TR Sub-Idx ETN (NYSE: PGM) Up 6.10%, as platinum futures are down about 1.4%. Investors might be looking for exposure in a different metals other than gold and silver, as many commodities have been having a good year so far.
Health Care Select Sector SPDR (NYSE: XLV) up about 0.50%. Major holdings include Johnson & Johnson (NYSE: JNJ), Bristol Meyers (NYSE: BMY), and Pfizer (NYSE: PFE). Bristol Meyers announced a deal to develop Alder's arthritis drug today.
<> Semiconductor HOLDRs (NYSE: SMH) up 0.4% today. There were ...
|
Big Pharma & Biotech – Industry Outlook
|
|
|
The pharmaceutical industry has witnessed major changes in 2009. Performance has been affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses.
According to IMS Health (RX), this is the main reason why global pharmaceutical market growth will be restricted to the mid-single digits through 2013. Over the next five years, products that currently generate about $137 billion in sales are expected to face generic co...
|
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
Visit streetinsider.com
|
|
|
|
fas831
(-8.08% risk: conservative)
|
|
Johnson & Johnson vs 3M
- I have been waiting and waiting for JNJ to drop but its really dissapointing seeing such a steady stock..on the other hand is 3M who is JNJ's competito
|
More Resources
|
About Johnson & Johnson
- Answers.com
